EcoDrugPlus

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSCGOG00000015901
Gene Symbol: HCK
3 Cross references
203 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSCGOG00000019792
Gene Symbol: ITK
3 Cross references
208 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSCGOG00000021992
Gene Symbol: JAK1
3 Cross references
214 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSCGOG00000020759
Gene Symbol: KRAS
3 Cross references
208 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSCGOG00000013040
Gene Symbol: MALT1
2 Cross references
198 Possible Orthologues:

Map Kinase-Activated Protein Kinase 2-Like

Ensembl ID : ENSCGOG00000007435
Gene Symbol: LOC115011375
3 Cross references
174 Possible Orthologues:

Map Kinase-Interacting Serine/threonine-Protein Kinase 2-Like

Ensembl ID : ENSCGOG00000007786
Gene Symbol: LOC115006668
3 Cross references
208 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSCGOG00000016045
Gene Symbol: MAPKAPK2
3 Cross references
186 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSCGOG00000000254
Gene Symbol: MAPKAPK5
3 Cross references
179 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSCGOG00000011876
Gene Symbol: MET
3 Cross references
204 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSCGOG00000007209
Gene Symbol: MLST8
3 Cross references
195 Possible Orthologues:

Nad(P)h Dehydrogenase [Quinone] 1-Like

Ensembl ID : ENSCGOG00000021438
Gene Symbol: LOC115026425
3 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).